Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | ADAM10 | O14672 | 3/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | QDPR | P09417 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21714595 | 0.84 | MAPT (0.44) | ADAM10MMP2QDPR | |
| SCHEMBL5320102 | 0.84 | PDK4 (0.53) | NAMPTJAK1KDM1AELANE | |
| SCHEMBL17672676 | 0.82 | ALK (0.42) | NAMPTSLC6A4LIMK1LIMK2JAK1 | |
| SCHEMBL18186201 | 0.81 | MAPT (0.40) | ADAM10MMP2LIMK1LIMK2QDPR | |
| SCHEMBL28504627 | 0.81 | MAPT (0.40) | SLC6A4ADAM10MMP2LIMK1LIMK2 | |
| SCHEMBL16422890 | 0.81 | MAPT (0.44) | SLC6A4LIMK1LIMK2QDPR | |
| SCHEMBL5805903 | 0.80 | NAMPT (0.47) | NAMPTQDPR | |
| SCHEMBL3457875 | 0.78 | NAMPT (0.51) | NAMPTADAM10MMP2HRH2HRH1 | |
| SCHEMBL25226634 | 0.78 | LIMK1 (0.46) | NAMPTLIMK1LIMK2 | |
| SCHEMBL6345407 | 0.78 | SLC6A4 (0.69) | SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250789-A1 | Hydroxamic acid derivatives as metalloprotease inhibitors | INCYTE CORPORATION | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250789-A1 | Hydroxamic acid derivatives as metalloprotease inhibitors | MMP9, MMP17, MMP25 | NAMPT 322/4885SLC6A4 2342/4885ADAM10 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.